Risk Factors for Neuropsychiatric Manifestations in Children With Systemic Lupus Erythematosus: Case-Control Study

被引:12
作者
Zuniga Zambrano, Yenny Carolina [1 ]
Guevara Ramos, Juan David [2 ]
Penagos Vargas, Nathalia Elena [1 ]
Benitez Ramirez, Diana Carol [1 ]
Ramirez Rodriguez, Sandra Milena [1 ]
Vargas Nino, Adriana Carolina [1 ]
Izquierdo Bello, Alvaro Hernando [3 ]
机构
[1] Univ Nacl Colombia, Dept Pediat, Pediat Neurol Program, Bogota, Colombia
[2] Hosp de la Misericordia Fdn, Div Child Neurol, Bogota, Colombia
[3] Univ Nacl Colombia, Dept Pediat, Pediat Neurol Program, Hosp de la Misericordia Fdn, Bogota, Colombia
关键词
systemic lupus erythematosus; neuropsychiatric systemic lupus erythematosus; children; adolescents; case-control study; ANTIPHOSPHOLIPID ANTIBODIES; DISEASE-ACTIVITY; COLLEGE; DAMAGE; ASSOCIATION; PREVALENCE; PREDICTORS; MANAGEMENT; SYMPTOMS; OUTCOMES;
D O I
10.1016/j.pediatrneurol.2014.03.027
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND: Neuropsychiatric symptoms in children with systemic lupus erythematosus cause high morbidity and disability. This study analyzed risk factors associated with neuropsychiatric presentation in patients with systemic lupus erythematosus aged <18 years. METHODS: A case-control study was performed. Medical record information of patients with a diagnosis of systemic lupus erythematosus who were hospitalized with or without neuropsychiatric symptoms was collected between March 2007 and January 2012. Clinical variables, laboratory examinations, neuroimages, and disease activity (Systemic Erythematosus Lupus Disease Activity Index) and damage (Systemic Lupus International Collaborating Clinics) indices were analyzed. RESULTS: A total of 90 patients were selected, 30 with neuropsychiatric symptoms. The patients' average age was 12.2 years. The most common neuropsychiatric symptoms were seizures, migraine, and depression. The average Systemic Erythematosus Lupus Disease Activity Index was 19.86 (S.D. 10.83) and the average Systemic Lupus International Collaborating Clinics index was 2.02 (S.D. 2.43), with higher values in patients with neuropsychiatric symptoms (P = 0.001). The levels of complement C3 and C4 were significantly higher in patients with a neuropsychiatric disorder (P = 0.003). Lupus anticoagulant was found in 51.5% of patients with neuropsychiatric symptoms (odds ratio, 3.7; 95% confidence interval, 1.3-10.0). Immunosuppression with azathioprine, rituximab, or cyclophosphamide delayed the time to neuropsychiatric systemic lupus erythematosus development by 18.5 months (95% confidence interval, 10.6-26.5) compared to patients who did not receive these agents. CONCLUSIONS: The presence of lupus anticoagulant was a risk factor in our patients. The use of immunosuppressants, such as cyclophosphamide, rituximab, and azathioprine, delayed the presentation of neuropsychiatric manifestations of lupus.
引用
收藏
页码:403 / 409
页数:7
相关论文
共 50 条
  • [21] Attribution of Neuropsychiatric Manifestations to Systemic Lupus Erythematosus
    Bortoluzzi, Alessandra
    Scire, Carlo Alberto
    Govoni, Marcello
    FRONTIERS IN MEDICINE, 2018, 5
  • [22] Neuroimmunological study in a patient with neuropsychiatric manifestations in systemic lupus erythematosus
    Martinez Larrarte, Jose Pedro
    Padilla-Docal, Barbara
    Juan Dorta-Contreras, Alberto
    Poalasin Narvaez, Luis Alberto
    Zamora Omar, Fernandez
    REVISTA CUBANA DE REUMATOLOGIA, 2014, 16 (03): : 385 - 390
  • [23] Neuropsychiatric and neuropsychological manifestations of Systemic Lupus Erythematosus
    Rios-Florez, Jorge Alexander
    Escudero-Corrales, Carolina
    Rocio Lopez-Gutierrez, Claudia
    REVISTA CUBANA DE REUMATOLOGIA, 2018, 20 (01):
  • [24] A case-control study on health-related quality of life of systemic lupus erythematosus patients
    Refai, Rania H.
    Hussein, Mohammed F.
    Abdou, Mamdouh H.
    Abou-Raya, Anna N.
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [25] Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case-control study
    Garcia-Carrasco, Mario
    Mendoza-Pinto, Claudia
    Munguia-Realpozo, Pamela
    Mendez-Valderrabano, Fabiola
    Mendez Martinez, Socorro
    Etchegaray Morales, Ivet
    Montiel-Jarquin, Alvaro
    Lopez-Colombo, Aurelio
    Schmulson, Max
    NEUROGASTROENTEROLOGY AND MOTILITY, 2019, 31 (11)
  • [26] Mimickers of neuropsychiatric manifestations in systemic lupus erythematosus
    de Amorim, Jaqueline Cristina
    Torricelli, Aline Kuhl
    Frittoli, Renan Bazuco
    Lapa, Aline Tamires
    Dertkigil, Sergio San Juan
    Reis, Fabiano
    Costallat, Lilian T. L.
    Franca Junior, Marcondes Cavalcante
    Appenzeller, Simone
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2018, 32 (05): : 623 - 639
  • [27] Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus
    Shimojima, Y
    Matsuda, M
    Gono, T
    Ishii, W
    Ikeda, S
    CLINICAL RHEUMATOLOGY, 2005, 24 (05) : 469 - 475
  • [28] Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus
    Yasuhiro Shimojima
    Masayuki Matsuda
    Takahisa Gono
    Wataru Ishii
    Shu-ichi Ikeda
    Clinical Rheumatology, 2005, 24 : 469 - 475
  • [29] Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study
    Haque, Sahena
    Gordon, Caroline
    Isenberg, David
    Rahman, Anisur
    Lanyon, Peter
    Bell, Aubrey
    Emery, Paul
    McHugh, Neil
    Teh, Lee Suan
    Scott, David G. I.
    Akil, Mohamed
    Naz, Sophia
    Andrews, Jacqueline
    Griffiths, Bridget
    Harris, Helen
    Youssef, Hazem
    McLaren, John
    Toescu, Veronica
    Devakumar, Vinodh
    Teir, Jamal
    Bruce, Ian N.
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (02) : 322 - 329
  • [30] Hematological malignancies in systemic lupus erythematosus: clinical characteristics, risk factors, and prognosis—a case-control study
    Yuqi Zhang
    Wei Li
    Panpan Zhang
    Jinyan Guo
    Jinlei Sun
    Jiameng Lu
    Shengyun Liu
    Arthritis Research & Therapy, 24